96 completed. 96 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 96 | Completed 96 |
| Phase 2 | 1 | Completed 1 |
Follow Pasteurellaceae Infections: new trials by email Literature Review of Pasteurellaceae Infections trials Research Report on Pasteurellaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Confirmatory Study of BK1310 in Healthy Infants DPT-IPV-Hib, Hib vaccine, DPT-IPV - Tetanus, Diphtheria | Phase 3 | Completed | Tanabe Pharma Corporation | 267 | 2019-04-01 | 2026-01-06 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants DPT-IPV-Hib (Combined Vaccine) - Immunization | Phase 3 | Completed | Tanabe Pharma Corporation | 33 | 2017-06-23 | 2026-01-06 |
| Phase 3 Study of BK1310 in Healthy Infants DPT-IPV-Hib-High（Combined Vaccine）, DPT-IPV-Hib-Low（Combined Vaccine）, Hib vaccine - Immunization; Infection | Phase 3 | Completed | Tanabe Pharma Corporation | 370 | 2016-11-01 | 2026-01-06 |
| A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Infanrix-IPV/Hib - Diphtheria, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 235 | 2016-09-13 | 2019-09-24 |
| A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 320 | 2015-06-11 | 2018-08-02 |
| Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth Hexaxim® - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 354 | 2015-04-20 | 2022-04-05 |
| Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children Hib-CRM197, Hib-TT - Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b | Phase 3 | Completed | Novartis Vaccines | 426 | 2014-11-01 | 2015-11-09 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
| DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants DTaP-IPV-Hep B-PRP~T combined vaccine, DTaP-IPV//PRP~T and Hepatitis B vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 310 | 2014-03-01 | 2017-04-26 |
| Phase III Study of Intramuscular TAK-816 in Healthy Infants TAK-816 - Healthy Volunteers, Haemophilus Influenzae Type b, Prevention | Phase 3 | Completed | Takeda | 31 | 2014-03-01 | 2016-04-26 |
| Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 600 | 2014-02-01 | 2018-09-14 |
| Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine, DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine, Infanrix hexa + Prevenar + Rotarix vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 558 | 2013-10-01 | 2016-01-05 |
| A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Quinvaxem in Uniject, Quinvaxem in single dose vials - Diphtheria, Pertussis | Phase 3 | Completed | Crucell Holland BV | 400 | 2013-09-01 | 2014-07-15 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers Infanrix-IPV+Hib™ - Acellular Pertussis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 321 | 2012-12-08 | 2020-01-21 |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine Infanrix hexa™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 224 | 2012-04-16 | 2020-01-02 |
| Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) PR5I, Rotavirus vaccine, Prevenar 13™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | MCM Vaccines B.V. | 1315 | 2011-11-23 | 2019-04-02 |
| Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine Infanrix+Hib™, Poliorix™ - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 831 | 2011-10-01 | 2018-06-06 |
| Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) V419, INFANRIX™ hexa, RotaTeq - Bacterial Infections, Virus Diseases | Phase 3 | Completed | MCM Vaccines B.V. | 1250 | 2011-05-26 | 2019-04-30 |
| A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) V419, PENTACEL™, Prevnar 13™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2808 | 2011-05-10 | 2018-11-15 |
Showing 20 of 96. Sign in to see all of them.
Haemophilus Infections (95) · Diphtheria (58) · Tetanus (57) · Hepatitis B (44) · Whooping Cough (41) · Poliomyelitis (37) · Streptococcal Infections (6) · Virus Diseases (6) · Infections (5) · Bacterial Infections (4) · Chickenpox (4) · Measles (4) · Mumps (4) · Rubella (4) · Influenza, Human (3)
Bacterial Infections and Mycoses (96) · Gram-Negative Bacterial Infections (95) · Bacterial Infections (92) · Infections (91) · Gram-Positive Bacterial Infections (66) · Actinomycetales Infections (58) · Corynebacterium Infections (58) · Clostridium Infections (57) · Virus Diseases (56) · DNA Virus Infections (47) · Respiratory Tract Diseases (46) · Blood-Borne Infections (45) · Communicable Diseases (45) · Digestive System Diseases (44)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (15) · Hiberix (12) · Vaccines (11) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (10) · Heptavalent Pneumococcal Conjugate Vaccine (10) · Pentavac (7) · 13-valent pneumococcal vaccine (6) · pentacel (6) · DTaP-IPV-HB-PRP-T vaccine (5) · Diphtheria-Tetanus-acellular Pertussis Vaccines (5) · Hepatitis A Vaccines (5) · PEDIARIX (5) · RIX4414 vaccine (5) · measles, mumps, rubella, varicella vaccine (5) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (4)
GlaxoSmithKline (46) · Sanofi Pasteur, a Sanofi Company (19) · Sanofi (8) · Novartis Vaccines (6) · Merck Sharp & Dohme LLC (4) · Tanabe Pharma Corporation (3) · Crucell Holland BV (2) · Forest Laboratories (2) · MCM Vaccines B.V. (2) · Heinrich-Heine University, Duesseldorf (1) · LG Chem (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Takeda (1)
United States (14) · China (12) · Philippines (10) · Germany (7) · Thailand (7) · India (6) · Mexico (6) · Poland (6) · Spain (6) · South Africa (5) · Argentina (4) · Finland (4) · Japan (4) · South Korea (4) · Peru (3)
Anne Fiquet, MD (1) · Dagmar Dilloo, MD, PhD (1) · Edison Alberto, MD (1) · IM Hoepelman, MD (1) · Josefina Carlos, MD (1) · Maria RZ Capeding, MD (1) · Ronald H. Gray, MD (1)
PMID 17716936, PMID 21482570, PMID 22327493, PMID 23357290, PMID 23964690, PMID 25487791, PMID 26702925, PMID 30597021, PMID 34922058, PMID 34986178, PMID 17090650, PMID 17321311, PMID 17545184, PMID 18086100, PMID 18463125, PMID 18532873, PMID 19117896, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19571722, PMID 19936044, PMID 20370483, PMID 20950456, PMID 21216000, PMID 21219984, PMID 21289531, PMID 21334243, PMID 21482566, PMID 21482568, PMID 21807056, PMID 21875633, PMID 22001281, PMID 22157567, PMID 22210632, PMID 22273029, PMID 22349525, PMID 22531237, PMID 22691430, PMID 23158882, PMID 23340564, PMID 23966556, PMID 24287186, PMID 25127244, PMID 25278086, PMID 25765966, PMID 26094162, PMID 26284652, PMID 27125273, PMID 27145999
2008 (3)